Compare IPWR & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPWR | PASG |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 28.6M |
| IPO Year | 2013 | 2020 |
| Metric | IPWR | PASG |
|---|---|---|
| Price | $3.34 | $11.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $10.75 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 76.8K | 50.9K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,136.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,233.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.76 | $5.12 |
| 52 Week High | $8.62 | $20.20 |
| Indicator | IPWR | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 66.92 |
| Support Level | $2.76 | $9.56 |
| Resistance Level | $3.36 | $11.50 |
| Average True Range (ATR) | 0.31 | 1.04 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 31.58 | 84.05 |
Ideal Power Inc is pioneering the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.